Last reviewed · How we verify
Esomeprazole (Intravenous)
Esomeprazole is a proton pump inhibitor that irreversibly blocks gastric H+/K+-ATPase, reducing gastric acid secretion.
Esomeprazole is a proton pump inhibitor that irreversibly blocks gastric H+/K+-ATPase, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Stress ulcer prophylaxis in critically ill patients.
At a glance
| Generic name | Esomeprazole (Intravenous) |
|---|---|
| Also known as | Esomeprazole Sodium |
| Sponsor | LanZhou University |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Esomeprazole is the active S-enantiomer of omeprazole that selectively inhibits the proton pump in gastric parietal cells, preventing the final step of gastric acid production. By suppressing acid secretion, it raises intragastric pH and is used to treat acid-related disorders. The intravenous formulation provides rapid onset of action for acute clinical situations.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Stress ulcer prophylaxis in critically ill patients
- Zollinger-Ellison syndrome
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Injection site reactions
- Hypomagnesemia (with chronic use)
Key clinical trials
- Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing (PHASE4)
- PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers (PHASE4)
- Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU
- Acid-suppression Drugs After Prophylactic Endoscopic Variceal Treatment of Esophagogastric Variceal Bleeding in Cirrhosis (NA)
- A Phase I Study of LX22001 for Injection in Healthy Subjects (PHASE1)
- Esomeprazole to Reduce Organ Failure in Sepsis (PHASE3)
- Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding (PHASE4)
- The Selection Criteria for the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Esomeprazole (Intravenous) CI brief — competitive landscape report
- Esomeprazole (Intravenous) updates RSS · CI watch RSS
- LanZhou University portfolio CI